NO20062975L - Anvendelse av T-kadherin som et mal - Google Patents

Anvendelse av T-kadherin som et mal

Info

Publication number
NO20062975L
NO20062975L NO20062975A NO20062975A NO20062975L NO 20062975 L NO20062975 L NO 20062975L NO 20062975 A NO20062975 A NO 20062975A NO 20062975 A NO20062975 A NO 20062975A NO 20062975 L NO20062975 L NO 20062975L
Authority
NO
Norway
Prior art keywords
disorder
modulators
cadherin
metabolic
template
Prior art date
Application number
NO20062975A
Other languages
English (en)
Norwegian (no)
Inventor
Christopher Hug
Harvey Lodish
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Publication of NO20062975L publication Critical patent/NO20062975L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
NO20062975A 2003-12-03 2006-06-26 Anvendelse av T-kadherin som et mal NO20062975L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52695603P 2003-12-03 2003-12-03
PCT/US2004/040363 WO2005057222A2 (en) 2003-12-03 2004-12-02 Use of t-cadherin as a target

Publications (1)

Publication Number Publication Date
NO20062975L true NO20062975L (no) 2006-06-26

Family

ID=34676687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062975A NO20062975L (no) 2003-12-03 2006-06-26 Anvendelse av T-kadherin som et mal

Country Status (18)

Country Link
US (1) US20070212686A1 (de)
EP (1) EP1701978B1 (de)
JP (1) JP2007519894A (de)
AT (1) ATE422506T1 (de)
AU (1) AU2004297914A1 (de)
CA (1) CA2546126A1 (de)
CY (1) CY1109014T1 (de)
DE (1) DE602004019451D1 (de)
DK (1) DK1701978T3 (de)
ES (1) ES2320139T3 (de)
HR (1) HRP20090119T3 (de)
IL (1) IL175862A (de)
NO (1) NO20062975L (de)
PL (1) PL1701978T3 (de)
PT (1) PT1701978E (de)
RS (1) RS50754B (de)
SI (1) SI1701978T1 (de)
WO (1) WO2005057222A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007204730B2 (en) 2006-01-10 2011-11-17 Colgate-Palmolive Company Methods of modulating cell surface receptors to prevent or reduce inflammation
CA2757425C (en) 2009-04-01 2015-06-30 Colgate-Palmolive Company Menthol-derivative compounds and use thereof as oral and systemic active agents
AR076041A1 (es) 2009-04-01 2011-05-11 Colgate Palmolive Co Biomarcadores de proteina para el diagnostico de enfermedades de tejido blando y como objetivos terapeuticos para intervenciones de cuidado oral
US8617523B2 (en) 2009-04-01 2013-12-31 Colgate-Palmolive Company Anti-biofilm carbonate compounds for use in oral care compositions
TWI405565B (zh) 2009-04-01 2013-08-21 Colgate Palmolive Co 口腔用組成物之抗-骨質流失及抗-牙周附連喪失之功效
GB201312010D0 (en) * 2013-07-04 2013-08-21 Univ Birmingham Receptor Agonists
WO2016100301A1 (en) * 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
EP4116711A4 (de) * 2020-03-03 2024-04-10 Tatsuya Sawamura Adiponectinquantifizierungsverfahren und analysereagens zur verwendung in besagtem verfahren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245048T3 (es) * 1997-10-15 2005-12-16 Pharis Biotec Gmbh Factor de crecimiento derivado de cadherina y su uso.
JP2002513804A (ja) * 1998-05-05 2002-05-14 アドヘレックス テクノロジーズ インコーポレイテッド 非古典的カドヘリン媒介機能を調節するための化合物および方法
US6680175B2 (en) * 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
AU2001232599B2 (en) * 2000-02-18 2006-10-12 Leangene Ab Transgenic animal model for obesity expressing foxc2
WO2002023184A1 (en) * 2000-09-13 2002-03-21 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
WO2002053726A2 (en) * 2001-01-02 2002-07-11 Hybrigenics Protein-protein interactions in adipocyte cells
EP1627229A2 (de) * 2003-04-29 2006-02-22 Cytos Biotechnology AG Verfahren und zusammensetzungen zur modulation der wechselwirkung zwischen adiponectin und dessen rezeptor
WO2005049861A2 (en) * 2003-11-10 2005-06-02 Epigenomics Ag Method for the analysis of gynaecological cell proliferative disorders

Also Published As

Publication number Publication date
ES2320139T3 (es) 2009-05-19
AU2004297914A1 (en) 2005-06-23
SI1701978T1 (sl) 2009-08-31
WO2005057222A3 (en) 2006-02-23
PT1701978E (pt) 2009-03-03
IL175862A (en) 2010-11-30
EP1701978B1 (de) 2009-02-11
DE602004019451D1 (de) 2009-03-26
CY1109014T1 (el) 2014-07-02
DK1701978T3 (da) 2009-04-06
PL1701978T3 (pl) 2009-07-31
US20070212686A1 (en) 2007-09-13
IL175862A0 (en) 2006-10-05
EP1701978A2 (de) 2006-09-20
JP2007519894A (ja) 2007-07-19
RS50754B (sr) 2010-08-31
HRP20090119T3 (en) 2009-04-30
WO2005057222A2 (en) 2005-06-23
CA2546126A1 (en) 2005-06-23
ATE422506T1 (de) 2009-02-15

Similar Documents

Publication Publication Date Title
CY1109014T1 (el) Χρηση της διαλυτης τ-καντερινης για την θεραπεια των διαταραχων του μεταβολισμου
NO20035526D0 (no) Forbindelser for behandling av metabolske forstyrrelser
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
DK1836169T5 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
DK1928850T3 (da) Midler til forebyggelse og behandling af lidelser, der involverer modulering af RyR-receptorerne
SG122901A1 (en) Positive type photo-sensitive siloxane composition, curing film formed by the composition and devicewith the curing film
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP4017007A4 (de) Bildcodierungsverfahren auf der grundlage einer transformation und vorrichtung dafür
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DK1761522T3 (da) Forbindelser og fremgangsmåder til behandling af dyslipidæmi
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
ECSP066877A (es) Moduladores canabinoides de tetrahidro-indazol
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
DK2350093T3 (da) Substituerede 4,5,6,7-tetrahydrothienopyridiner som KCNQ2/3-modulatorer til behandling af smerte, epilepsi og urininkontinens.
DE602005020313D1 (de) Bisaryl-sulfonamide
DK1383919T3 (da) Fremgangsmåder og sammensætninger til anvendelse af MHC klasse II-invariant kædepolypeptid som en receptor for makrofag migrationsinhiberede faktor
DE602006015126D1 (de) Randbelichtungsapparat, Beschichtungs- und Entwicklungsapparat und Randbelichtungsmethode
ATE492543T1 (de) 1,5-diphenyl-3-benzylamino-1,5-dihydropyrrolidi - 2-one als cb1-rezeptor-modulatoren
NO20073369L (no) Modulatorer av muskarinreseptorer
DK1725234T3 (da) Fremgangsmåder til behandling af lidelser eller sygdomme, der er forbundet med hyperlipidæmi og hyperkolesterolæmi, med minimering af bivirkninger
EP1993172A4 (de) Fixierer, den fixierer verwendende oberflächenanbringungskomponente und den fixierer verwendende anbringungsstruktur
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application